Cullinan Therapeutics, Inc. (CGEM) NASDAQ
15.21
-0.13(-0.85%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
15.21
-0.13(-0.85%)
Currency In USD
| Previous Close | 15.34 |
| Open | 15.35 |
| Day High | 15.46 |
| Day Low | 15.01 |
| 52-Week High | 16.74 |
| 52-Week Low | 5.68 |
| Volume | 775,946 |
| Average Volume | 883,284 |
| Market Cap | 934.78M |
| PE | -4.51 |
| EPS | -3.37 |
| Moving Average 50 Days | 14.48 |
| Moving Average 200 Days | 11.06 |
| Change | -0.13 |
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational